Trikafta FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 29, 2024.
FDA Approved: Yes (First approved October 21, 2019)
Brand name: Trikafta
Generic name: elexacaftor/tezacaftor/ivacaftor and ivacaftor
Dosage form: Tablets and Oral Granules
Company: Vertex Pharmaceuticals Incorporated
Treatment for: Cystic Fibrosis
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a triple combination regimen for the treatment of cystic fibrosis (CF) in patients ages 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data.
Development timeline for Trikafta
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.